Initiator Pharma A/S
Initiator Pharma A/S, a clinical stage life science company, develops drugs targeting unmet medical needs within the central and peripheral nervous system. Its product pipeline includes Pudafensine, a monoamine reuptake inhibitor, which completed phase IIb clinical trial primarily targeting the dopamine system for treatment resistant organic erectile dysfunction, as well as completed phase I to t… Read more
Initiator Pharma A/S (INIT) - Net Assets
Latest net assets as of September 2025: Skr32.47 Million SEK
Based on the latest financial reports, Initiator Pharma A/S (INIT) has net assets worth Skr32.47 Million SEK as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (Skr36.84 Million) and total liabilities (Skr4.37 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | Skr32.47 Million |
| % of Total Assets | 88.14% |
| Annual Growth Rate | N/A |
| 5-Year Change | 2.59% |
| 10-Year Change | N/A |
| Growth Volatility | 84.01 |
Initiator Pharma A/S - Net Assets Trend (2016–2024)
This chart illustrates how Initiator Pharma A/S's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Initiator Pharma A/S (2016–2024)
The table below shows the annual net assets of Initiator Pharma A/S from 2016 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | Skr14.78 Million | +32.43% |
| 2023-12-31 | Skr11.16 Million | -67.19% |
| 2022-12-31 | Skr34.02 Million | -2.77% |
| 2021-12-31 | Skr34.99 Million | +142.86% |
| 2020-12-31 | Skr14.41 Million | +45.43% |
| 2019-12-31 | Skr9.91 Million | -40.21% |
| 2018-12-31 | Skr16.57 Million | +177.83% |
| 2017-12-31 | Skr5.96 Million | +1707.55% |
| 2016-12-31 | Skr-371.00K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Initiator Pharma A/S's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 977700000.0% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | Skr8.88 Million | 60.11% |
| Common Stock | Skr5.90 Million | 39.89% |
| Total Equity | Skr14.78 Million | 100.00% |
Initiator Pharma A/S Competitors by Market Cap
The table below lists competitors of Initiator Pharma A/S ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Medicus Pharma Ltd. Common Stock
OTCBB:MDCX
|
$12.15 Million |
|
Cadrenal Therapeutics, Inc. Common Stock
NASDAQ:CVKD
|
$12.15 Million |
|
Electromagnetica SA
RO:ELMA
|
$12.15 Million |
|
Seojin Automotive Co.Ltd
KQ:122690
|
$12.15 Million |
|
Akobo Minerals AB (publ)
OL:AKOBO
|
$12.15 Million |
|
The INX Digital Company Inc.
OTCQB:INXDF
|
$12.15 Million |
|
Galena Mining Ltd
AU:G1A
|
$12.14 Million |
|
IL&FS Investment Managers Limited
NSE:IVC
|
$12.14 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Initiator Pharma A/S's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 11,162,000 to 14,782,000, a change of 3,620,000 (32.4%).
- Net loss of 12,932 reduced equity.
- Share repurchases of 690,000 reduced equity.
- New share issuances of 17,242,000 increased equity.
- Other factors decreased equity by 12,919,068.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | Skr-12.93K | -0.09% |
| Share Repurchases | Skr690.00K | -4.67% |
| Share Issuances | Skr17.24 Million | +116.64% |
| Other Changes | Skr-12.92 Million | -87.4% |
| Total Change | Skr- | 32.43% |
Book Value vs Market Value Analysis
This analysis compares Initiator Pharma A/S's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 0.01x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2016-12-31 | Skr-0.03 | Skr3.08 | x |
| 2017-12-31 | Skr725.66 | Skr3.08 | x |
| 2018-12-31 | Skr825.16 | Skr3.08 | x |
| 2019-12-31 | Skr408.71 | Skr3.08 | x |
| 2020-12-31 | Skr526.36 | Skr3.08 | x |
| 2021-12-31 | Skr997.32 | Skr3.08 | x |
| 2022-12-31 | Skr704.05 | Skr3.08 | x |
| 2023-12-31 | Skr0.21 | Skr3.08 | x |
| 2024-12-31 | Skr258.12 | Skr3.08 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Initiator Pharma A/S utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -0.09%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.03x
- Recent ROE (-0.09%) is above the historical average (-58.17%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2016 | 0.00% | 0.00% | 0.00x | 0.00x | Skr-854.90K |
| 2017 | -143.90% | 0.00% | 0.00x | 1.56x | Skr-9.18 Million |
| 2018 | -62.15% | 0.00% | 0.00x | 1.05x | Skr-11.96 Million |
| 2019 | -83.65% | 0.00% | 0.00x | 1.15x | Skr-9.28 Million |
| 2020 | -60.36% | 0.00% | 0.00x | 1.08x | Skr-10.14 Million |
| 2021 | -60.19% | 0.00% | 0.00x | 1.53x | Skr-24.56 Million |
| 2022 | -113.03% | 0.00% | 0.00x | 1.42x | Skr-41.86 Million |
| 2023 | -0.20% | 0.00% | 0.00x | 2.67x | Skr-1.14 Million |
| 2024 | -0.09% | 0.00% | 0.00x | 1.03x | Skr-1.49 Million |
Industry Comparison
This section compares Initiator Pharma A/S's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $60,327,288
- Average return on equity (ROE) among peers: -132.31%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Initiator Pharma A/S (INIT) | Skr32.47 Million | 0.00% | 0.13x | $12.15 Million |
| 2cureX AB (2CUREX) | $20.24 Million | -15.50% | 0.13x | $1.38 Million |
| Abliva AB (ABLI) | $63.04 Million | -23.59% | 0.13x | $46.60 Million |
| Ascelia Pharma AB (publ) (ACE) | $180.86 Million | -72.56% | 0.21x | $25.35 Million |
| AcouSort AB (ACOU) | $20.11 Million | -65.68% | 1.12x | $4.82 Million |
| Active Biotech AB (ACTI) | $162.30 Million | -107.35% | 0.93x | $3.55 Million |
| Alzinova AB (ALZ) | $29.39 Million | -8.53% | 0.08x | $4.19 Million |
| AlzeCure Pharma (ALZCUR) | $110.75 Million | -64.44% | 0.06x | $12.56 Million |
| Annexin Pharmaceuticals AB (ANNX) | $20.64 Million | -216.80% | 0.22x | $4.92 Million |
| Alligator Bioscience AB (ATORX) | $6.86 Million | -748.65% | 15.13x | $723.60K |
| Biosergen AS (BIOSGN) | $-10.92 Million | 0.00% | 0.00x | $2.76 Million |